MSD

News

MSD steps out with Protillion in $510m+ AI shindig

MSD has teamed up with Protillion Bio in a deal worth more than $510m, focusing on using the AI start-up's lab-in-the-loop platform for drug discovery

News

FDA starts kicks off review of Gilead's weekly HIV pill

The FDA is due to deliver a verdict in February on Gilead's once-weekly pill for HIV PrEP, which could expand the options available to patients.

News

MSD's Sac-TMT delivers in first phase 3 readout

MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.

News

NICE backs stomach cancer, PAH drugs for NHS use

AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.

News

MSD cuts $1bn AI tool deal with Google Cloud

MSD has agreed a deal with Google Cloud that will put the tech giant's AI tools in the hands of its 75,000 employees worldwide.

News

MSD, Eisai report setback in first-line kidney cancer trial

The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.

MSD steps out with Protillion in $510m+ AI shindig

FDA starts kicks off review of Gilead's weekly HIV pill

MSD's Sac-TMT delivers in first phase 3 readout

NICE backs stomach cancer, PAH drugs for NHS use

MSD cuts $1bn AI tool deal with Google Cloud

MSD, Eisai report setback in first-line kidney cancer trial

CHMP backs Novo's haemophilia A drug Frehemgo

Discover a new era of healthcare panel engagement: Grounded ...

MSD

Editor's Picks